Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

jul 11
Release date

Advances in the Management of Hematologic Malignancies - Highlights from the 2011 ASCO Annual Meeting

Multi-Topic Hematology

MEDIA: Newsletter

Estimated time to complete activity: 1.25 hours | Release date: Monday, July 11, 2011 | Expiration date: Tuesday, July 10, 2012


The 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, Illinois, June 3-7, 2011, presented a comprehensive view of the latest innovations in cancer research and future technologies. Highlights of this year's data and research in hematologic malignancies are included in this interactive newsletter.


Leukemia Update
Lymphoma Update
Multiple Myeloma Update


Christopher R. Flowers, MD, MSc

Associate Professor, Hematology and Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Gail J. Roboz, MD

Associate Professor of Medicine
Director, Leukemia Program
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Jeffrey L. Wolf, MD

Professor of Medicine
Director, Myeloma Program
Hematology/Oncology Division
Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California


The intended audience for this initiative includes hematologists, medical oncologists, hematologist oncologists, oncology specialty pharmacists, and oncology nurses charged with the care of patients with hematologic malignancies.


At the conclusion of this activity, participants should be able to:

  • Discuss implications of updated efficacy and safety data for clinically available treatment options for patients with hematologic malignancies
  • Describe potential role of new therapeutic agents or strategies into clinical practice to improve remission and survival rates for patients with hematologic malignancies
  • Describe the proposed mechanisms of action of new and emerging therapeutic agents in development for the management of patients with hematologic malignancies
  • Differentiate treatment regimens based upon efficacy and toxicity parameters


Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ACPE Logo Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Educational Concepts Group, LLC designates this continuing education activity for 1.25 contact hours (0.125 CEUs) (UAN 0199-0000-11-024-H01-P).

Type of activity: Knowledge-based


There are no fees for participating and receiving CME/CE credit for this activity. During the period Monday, July 11, 2011 through Tuesday, July 10, 2012, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.


Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.


It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Christopher R. Flowers, MD, MSc Grants/Research Support Eisai Inc.
Millennium Pharmaceuticals, Inc.
Pfizer Inc
Spectrum Pharmaceuticals, Inc.
Consultant Fees Celgene Corporation
Prescription Solutions
Gail J. Roboz, MD Consultant Fees Boehringer Ingelheim
ChemGenex Pharmaceuticals
Celgene Corporation
EpiCept Corporation
Jeffrey L. Wolf, MD Grants/Research Support Celgene Corporation
Speakers' Bureau Celgene Corporation
Millennium Pharmaceuticals, Inc.
Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.


The editors wish to thank Sara R. Fagerlie, PhD, for her assistance in writing this document.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.


This activity is supported by educational grants from the following: Celgene Corporation, Merck & Co., Inc.


For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

Yes, I have read the information above and am interested in participating.